

Supporting Information

Xie et al. 10.1073/pnas.1306263110




Fig. S1. Membrane-tethered thrombopoietin receptor (TPOR) agonist antibody (MTA-3D9) stimulates both reporter cell lines. (A) A TPOR lactamase reporter cell line is activated after infection by Lentivirus expressing the TPO agonist antibody (MTA-3D9). (B) A growth-based analysis. The Ba/F3-TPOR reporter cell line proliferates after infection by Lentivirus expressing antibody MTA-3D9. Cell growth was measured 2 d after virus infection and compared with treatment with the control TPO agonist antibody using a standard MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay. Each treatment was studied in triplicate. Cell growth was maximal after MTA-3D9 infection and addition of extra soluble agonist antibody had no effect.




Fig. S2. Establishment of the granulocyte colony-stimulating factor (G-CSF) reporter cell lines. (A) The Ba/F3-G-CSF receptor (G-CSFR) reporter cell line responds by growth to G-CSF treatment in a dose dependent manner. The cell growth is determined by a standard MTS assay. (B) The β -lactamase based G-CSF reporter cell line (SIE/BLA/SIG) responds to different doses of G-CSF treatment. After G-CSF induction, β -lactamase activity is measured by a FRET signal generated by hydrolysis of the CCF4-AM substrate within the cells.




Fig. S3. The preselected plasma membrane tethered antibody libraries activate the reporter cell line. (A) As a control, SIE/BLA/SIG cells were infected by lentiviruses expressing membrane tethered Tomato red fluorescence protein (MTA-Tomato) followed by incubation with the FRET substrate (CCF4-AM). These control cells showed little activation. (B) Treatment with 1 ng/mL G-CSF activates the majority of the cells. (C) The reporter cells were infected by the lentivirus antibody library that had been enriched by panning against the G-CSFR ectodomain. (D) The activated pool of cells from C was collected and the antibody genes were recovered. The genes were converted into a secondary MTA-antibody lentivirus library, and the reporter cells were infected again. In this second round a larger percentage of cells was induced. The same gate was applied to the four panels. The induced cells are indicated by a circle to underscore the differences between various treatments.




Fig. S4. The isolated soluble G-CSFR agonist antibody is capable of activating reporter cell lines. (A) The SIE/BLA/SIG cells were activated after the agonist antibody treatment. β -lactamase activity is measured by the FRET signal from hydrolysis of the CCF4-AM substrate. (B) The growth of the BaF3-G-CSFR cell line (BaF3-114) is stimulated by 2 d of treatment with the agonist antibody as measured by the MTS assay.




Fig. S5. The membrane tethered agonist antibody activated the G-CSFR reporter cells. (A) As a control, it was shown that the membrane tethered TPOR agonist antibody (MTA-3D9) does not activate the G-CSFR reporter cells. (B) G-CSF (1 ng/mL) treatment potently activates the reporter cells. (C) Lentivirus mediated delivery of the membrane-tethered agonist antibody activates the SIE/BLA/SIG cells.




Fig. S6. The response of the SIE/BLA/SIG cells are strictly receptor dependent. (A) G-CSF activates the reporter cell line in a dose-dependent manner (round dots/red fitted curve), whereas the base cells (SIE/BLA cells used for constructing the reporter cell line) that did not contain the G-CSFR did not respond to any dose of G-CSF (triangles/blue fitted curve). (B) The reporter cell line responds to the agonist antibody (3B3) in a dose dependent manner (red column), whereas the base cells have no response to any dose of 3B3 (green column). Both cell lines respond to treatment with IL-6.




Fig. 57. Typical morphology of the antibody induced cells. (A and B) Single cells that are attached to glass coverslips after 2 wk of treatment with the G-SCF agonist antibody. White arrows point to growth cones. (C) "Bi-polar" morphology of some cells after 10 d in culture. Arrows indicate long neuritis.





Fig. 58. (A–C) Nestin staining of the attached cells. Cells were cultured for 2 wk in the presence of the 3B3 antibody, fixed, and stained for Nestin (green). Actin is labeled by Phalloidin-eFluor 570 (red). (D and E). Extensive neurite length highlighted after Tuj-1 staining (green). Areas enriched for actin are red. White arrows highlight the “spine-like” bodies.

A



CD34 signaling change upon treatment.

B

Symbol	Up-Down Regulation (comparing to control group)		Description
	G-CSF treated	Antibody treated	
TNR	-17.7987	-12.9103	Tenascin R (restrictin, janusin)
NEUROG1	1.344	-2.8421	Neurogenin 1
PTN	2.1545	-2.2025	Netrin-1
ACSL1	1.2054	-1.7391	Acyl-CoA:cholesterol complex homolog 1 (Drosophila)
DOCK	-2.3975	-1.7391	Doublinortin
CDNF	20.3234	-1.7391	Craniol cell derived neurotrophic factor
NEUROD1	-2.3975	-1.7391	Neurogenesis differentiation 1
NF13	-2.3975	-1.7391	Neurogenin 3
NTN1	1.1248	-1.2385	Netrin 1
HEY2	4.9525	-1.1569	Helary enhancer of split related with YRPW motif 2
BMP4	1.586	1.0239	Bone morphogenetic protein 4
PAK5	19.6514	1.1347	Paired box 5
DRO2	-1.248	1.2383	Dopamine receptor D2
NOX	5.931	1.3017	Neogen
NRG1	1.7763	1.3452	Neuregulin 1
BCL2	1.9264	1.4693	B-cell CLL/lymphoma 2
NRG3	2.2133	1.6408	Nuclear receptor subfamily 2, group E, member 3
SHH	2.3488	1.6484	Sonic hedgehog
POLR1F	2.2664	1.6989	PCP class 4 homeobox 1
ACHE	-1.2539	2.0301	Acetylcholinesterase
FGA4	3.1959	2.308	Hyaluronidase 4
CHRM2	8.4601	2.3222	Cholinergic receptor, muscarinic 2
ALK	1.4887	2.2424	Anaplastic lymphoma receptor tyrosine kinase
NRXN	5.7699	2.5993	Adrenon
PAR3	1.8311	2.5873	Par-3 partitioning defective 3 homolog (C. elegans)
PAR6B	3.9234	2.575	Bone morphogenetic protein 6b
FGF	4.9774	2.7429	Fibroblast growth factor 2 (basic)
EP300	2.6375	2.9274	E1A binding protein p300
GRIN1	1.1458	3.0471	Glutamate receptor, ionotropic, N-methyl D-aspartate 1
DVA3	2.0741	3.1854	Dihydrated, ash homolog 3 (Drosophila)
CKIR1	3.5549	3.4989	Cytlin-dependent kinase 5, regulatory subunit 1 (p35)
NEURO2	1.3973	3.669	Neurogenin 2
BDNF	11.1987	3.0273	Brain-derived neurotrophic factor
VEGFA	3.1545	3.1264	Vascular endothelial growth factor A
HEY1	3.1789	3.1448	Helary enhancer of split related with YRPW motif-like
FGF8	2.1744	3.4713	Transforming growth factor, beta 1
BMP2	2.5159	4.0274	Bone morphogenetic protein 2
HEY2	-1.2668	4.1309	Helary enhancer of split related with YRPW motif 1
CAPDH	3.3393	4.1463	Glyceroldehyde-3-phosphate dehydrogenase
MLL	4.9811	4.3751	Mutated lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila)
HELI1	5.5399	4.399	Helary and enhancer of split 1 (Drosophila)
ROBO1	2.9341	4.6899	Roundabout, axon guidance receptor, homolog 1 (Drosophila)
DLG4	3.3995	4.6924	Discs, large homolog 4 (Drosophila)
PAR6B	2.9433	5.111	Par-6b beta (beta) precursor protein-binding, family B, member 1 (F465)
NF1	4.3342	5.4718	Neurofibromin 1
HRP11	4.6123	5.6984	Hypoxanthine phosphoribosyltransferase 1
PAK1	4.1448	5.6948	Paired box 3
ERBB2	5.6799	6.1249	V-erb-B2 erythroblastic leukemia viral oncogene homolog 2, neurofiblastoma derived oncogene homolog (avian)
SOX3	-1.8284	6.1492	SOX3 (sex determining region Y) box 3
PCP3F3	-1.784	6.4601	PCP class 3 homeobox 3
REPC	21.1181	6.1164	Epidermal growth factor
FLNA	7.8053	6.8011	Filipin enhancer factor 2C
FLNA	4.3488	7.5718	Filamin A, alpha
PAR6B1	5.167	7.4	Par-6b beta (beta) precursor protein-binding, family B, member 1 (F465)
S100A6	4.4917	7.6963	S100 calcium binding protein A6
RHO1	5.3771	8.0291	Rac1
FLT3	1.9798	8.6863	Flt3 homolog 2 (Drosophila)
EFNB1	5.1437	8.6989	Egfrin-B1
SOD1	6.3295	9.1233	Superoxide dismutase 1, soluble
GPI	9.7885	9.1892	Glucose-6-phosphate isomerase
PAK1	8.5541	9.0274	Paired box 6
MYO2	5.9311	12.0421	Myosin 2
CREB1	10.3732	12.2892	CREB responsive element binding protein 1
ARP	11.1269	12.1773	Arp2/3 beta (beta) precursor protein
NRP2	2.2078	14.6071	Neuropilin 2
S100B	2.5499	14.7818	S100 calcium binding protein B
NRK	29.214	15.514	Neurite growth-promoting factor 2
RPLP0	17.0713	16.7011	Ribosomal protein, large, P0
RAC1	8.9338	16.8001	Ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1)
STAT3	12.4851	17.2221	Signal transducer and activator of transcription 3 (acute-phase response factor)
SOX1	6.8929	17.3976	SOX (sex determining region Y) box 2
CKCL1	6.9272	18.31	Cem6-like (C-6C motif) ligand 1 (metastoma growth stimulating activity, alpha)
CKIRAP2	4.1843	18.004	CKIR3 regulatory subunit associated protein 2
ADORA2A	11.1094	20.1573	Adenosine A2a receptor
B2M	14.186	20.6518	Beta-2-microglobulin
ACTB	16.1094	24.9336	Actin, beta
PCLO2	3.308	24.3751	Oligodendrocyte lineage transcription factor 2
IL3	5.3152	30.1039	Interleukin 3 (colony-stimulating factor, multiple)
RTN4	17.8168	33.881	Relican 4
NDN	16.5192	33.6451	Neclin homolog (mouse)
NRP1	6.0134	34.2299	Neuropilin 1
DOCK1	41.799	36.0595	Dock, ood O2/m-homolog 1 (Drosophila)
DLL1	3.3423	43.2457	Delta-like 1 (Drosophila)
TH	22.2178	47.2974	Tyrosine hydroxylase
MMP2	52.128	55.5154	Matrix metallo-associated protein 2
APDE	-1.285	57.7622	Apoptogen E
NRCAM	-2.195	66.8107	Neuronal cell adhesion molecule
NRP	3.1484	229.5542	Neurite disease (neuropiloma)
ADORA1	8.8274	314.938	Adenosine A1 receptor

Fig. S9. (A) G-CSFR downstream signaling differs depending on the activators. CD34+ cells were treated with either the agonist antibody or G-CSF and the lysates were analyzed by Western blots using phosphorylation specific antibodies. (B) Quantitative PCR (qPCR)-based array analysis of the expression of 84 neurogenesis-related genes. The gene expression in control untreated CD34+ bone marrow cells was compared with either G-CSF or antibody treated cells after 2 wk in culture. All cells were from the same harvest and were simply divided into three parts. After culture, the RNA was extracted and cDNA was prepared. The cDNA was added to an array of 84 wells, each of which contained a different set of PCR primers for a gene related to neurogenesis. qPCR was carried out on the BioRad CFX-96 machine, and the data were analyzed by a web-based tool on SABioscience.com. An equal threshold was set to allow accurate comparison across samples, and the data were normalized to wells having the least variation according to the manufacturer's instructions.